about
Nanoparticulate adjuvants and delivery systems for allergen immunotherapyPreferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.Malaria vaccine development and how external forces shape it: an overview.Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cellsAHAPS-functionalized silica nanoparticles do not modulate allergic contact dermatitis in miceCanine recombinant adenovirus vector induces an immunogenicity-related gene expression profile in skin-migrated CD11b⁺ -type DCs.Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response.Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model.Chitosan-based systems for the delivery of vaccine antigens.Progress towards a needle-free hepatitis B vaccine.Topical and mucosal liposomes for vaccine delivery.Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.Selective hair therapy: bringing science to the fiction.Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.A microarray MEMS device for biolistic delivery of vaccine and drug powdersDevelopment and in vitro evaluation of a nanoemulsion for transcutaneous delivery.Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy
P2860
Q26825418-9777AA5B-7A7D-4C8D-93B3-DC1316110361Q33593103-A7F728EF-07B4-4B4B-89CF-6BC19CEA85C7Q33963746-47CCCC02-8E2A-4AE1-89E9-8454DC98988AQ34059945-EB87BA48-87FC-41C1-8B84-503EFE87A4A6Q34121001-D92D9557-5A39-4000-AA60-563E40CA087BQ34254990-9C03FD95-3FDB-459E-98B1-0FA90A003F2FQ34540809-93DB29AD-D6BA-4597-93A4-C3A860EA3440Q36998403-5384C538-67A7-4AF7-876C-1574B6122BB0Q37521185-9A82987D-4CE2-4BF6-9ADD-3D06EBEE94A3Q37524050-C907FD29-2328-4BAF-BBF0-84C7EC4969EBQ37810816-DF07FCC6-F73D-4FF9-A254-76C98304BC75Q37848296-1BA3339B-7557-488F-870E-7094EB04E1F7Q38066148-45AB0010-9450-4FF7-A5A6-B912A68D6C97Q38175504-4EB082EE-AC30-4073-89CB-D40BE7EC7BE3Q38285751-E051F74B-ED77-4190-915A-55265EB49306Q38418305-D95A4C60-2C2E-45CD-9C3A-40CFF033725CQ38993921-C485D85E-2274-49D6-AC93-D6759708DE9DQ42244601-1746302B-073C-4D13-94EA-3F07781A47B1Q57492118-986B7DF3-D768-4AA6-A1DC-0B6552067455
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Particle-based vaccines for transcutaneous vaccination.
@en
type
label
Particle-based vaccines for transcutaneous vaccination.
@en
prefLabel
Particle-based vaccines for transcutaneous vaccination.
@en
P1476
Particle-based vaccines for transcutaneous vaccination.
@en
P2093
Behazine Combadière
Brice Mahé
P304
P356
10.1016/J.CIMID.2007.07.015
P577
2007-10-30T00:00:00Z